Intravascular studies with iohexol (Omnipaque). Results from the first 49 clinical trials.

  • Andrew E
  • Dahlstrøm K
  • Sveen K
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • 10

    Citations

    Citations of this article.

Abstract

In order to assess the vascular clinical trial program of iohexol (Omnipaque) in Europe, the results from the first 49 vascular trials are collectively reported. The included iohexol material comprises 1742 patients. In 40 comparative trials, other contrast media like metrizamide (Amipaque), ioxaglate (Hexabrix) and various monomeric ionic media were administered in 1292 patients included in this analysis. No severe or unexpected adverse reactions related to iohexol were encountered. No clinically significant differences in radiographic image quality between the media were documented. The overall tolerability of iohexol was superior to that of monomeric ionic media and seemed to be as good as that of metrizamide.

Author-supplied keywords

  • Adolescent
  • Adult
  • Aged
  • Angiocardiography
  • Angiography
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Female
  • Humans
  • Infant
  • Injections, Intra-Arterial
  • Injections, Intravenous
  • Iodobenzoates
  • Iodobenzoates: administration & dosage
  • Iohexol
  • Male
  • Middle Aged
  • Phlebography
  • Tomography, Emission-Computed
  • Triiodobenzoic Acids
  • Triiodobenzoic Acids: administration & dosage
  • Triiodobenzoic Acids: adverse effects
  • Urography

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • ISSN: 0720-048X
  • PMID: 3891345
  • PUI: 15139895
  • SGR: 0021992571
  • SCOPUS: 2-s2.0-0021992571

Authors

  • E Andrew

  • K Dahlstrøm

  • K Sveen

  • G Hvinden

  • T Holager

  • P Mowinckel

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free